Jingxin Liu Selected Research

helenalin

1/2021	Antitumor effects of helenalin in doxorubicin-resistant leukemia cells are mediated via mitochondrial mediated apoptosis, loss of mitochondrial membrane potential, inhibition of cell migration and invasion and downregulation of PI3-kinase/AKT/m-TOR signalling pathway.
9/2019	Antitumor effects of helenalin in doxorubicin-resistant leukemia cells are mediated via mitochondrial mediated apoptosis, loss of mitochondrial membrane potential, inhibition of cell migration and invasion and downregulation of PI3-kinase/AKT/m-TOR signalling pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jingxin Liu Research Topics

Disease

5	Obesity 05/2021 - 01/2019
3	Insulin Resistance 05/2021 - 12/2014
2	Breast Neoplasms (Breast Cancer) 12/2022 - 01/2019
2	Non-alcoholic Fatty Liver Disease 11/2021 - 01/2020
2	Inflammation (Inflammations) 06/2021 - 10/2020
2	Leukemia 01/2021 - 09/2019
2	Shock 01/2020 - 01/2020
2	Weight Loss (Weight Reduction) 03/2019 - 01/2019
2	Neoplasms (Cancer) 01/2019 - 12/2015
2	Epilepsy (Aura) 06/2015 - 06/2014
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2022
1	Cushing Syndrome 01/2022
1	Fatty Liver 11/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 10/2020
1	Dehydration (Water Stress) 04/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 09/2019
1	Overweight 03/2019
1	Muscle Weakness 01/2019
1	Body Weight (Weight, Body) 01/2019
1	Atrophy 01/2019
1	Muscular Atrophy (Muscle Atrophy) 01/2019
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2018
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2014
1	Diabetes Complications 01/2013
1	Hyperglycemia 01/2013

Drug/Important Bio-Agent (IBA)

3	Triglycerides (Triacylglycerol)IBA 11/2021 - 01/2020
3	Sirtuin 3IBA 10/2020 - 01/2020
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2019
2	Glucose (Dextrose)FDA LinkGeneric 05/2021 - 01/2013
2	helenalinIBA 01/2021 - 09/2019
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 09/2019
2	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2021 - 09/2019
2	CytokinesIBA 10/2020 - 12/2014
2	myricanolIBA 01/2019 - 01/2019
2	Transcription Activator-Like Effector NucleasesIBA 06/2015 - 06/2014
1	Estrogens (Estrogen)FDA Link 12/2022
1	Bile Acids and Salts (Bile Acids)IBA 01/2022
1	Choline (Choline Chloride)IBA 11/2021
1	SteroidsIBA 06/2021
1	HDL CholesterolIBA 05/2021
1	oxidized low density lipoproteinIBA 05/2021
1	CholesterolIBA 05/2021
1	Insulin (Novolin)FDA Link 05/2021
1	LDL CholesterolIBA 05/2021
1	MicroRNAs (MicroRNA)IBA 01/2021
1	AMP-Activated Protein KinasesIBA 10/2020
1	InflammasomesIBA 10/2020
1	HydrocarbonsIBA 04/2020
1	Perilipin-1IBA 01/2020
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2020
1	Lysosomal Membrane ProteinsIBA 01/2020
1	LactonesIBA 09/2019
1	Pharmaceutical PreparationsIBA 09/2019
1	SesquiterpenesIBA 09/2019
1	Matrix Metalloproteinases (MMPs)IBA 09/2019
1	Biological ProductsIBA 03/2019
1	Fatty Acids (Saturated Fatty Acids)IBA 03/2019
1	LipidsIBA 01/2019
1	Adenosine Triphosphate (ATP)IBA 01/2019
1	GlucocorticoidsIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Coloring Agents (Dyes)IBA 01/2019
1	Myosin Heavy Chains (Myosin Heavy Chain)IBA 01/2019
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019
1	Sirtuin 1IBA 01/2019
1	Muscle Proteins (Muscle Protein)IBA 01/2019
1	Formaldehyde (Formol)FDA Link 02/2018
1	ParaffinIBA 02/2018
1	ErbB Receptors (EGF Receptor)IBA 02/2018
1	DNA (Deoxyribonucleic Acid)IBA 02/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2014
1	N-formyl-13-dihydrocarminomycin (NFD)IBA 12/2014
1	CarbohydratesIBA 01/2013
1	FlavonoidsIBA 01/2013
1	GlucosidasesIBA 01/2013
1	EnzymesIBA 01/2013

Therapy/Procedure

4	Therapeutics 01/2022 - 12/2015